Evaluation of the effect of silymarin on cholesterol triglyceride and BMI in patients with type 2 diabetes mellitus referring to endocrine clinic of Imam khomeini hospital Urmia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170814035697N4

Enrollment

Registered

2019-10-06

Start date

2019-05-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BMI and Lipid profile in type 2 DM. R4

Interventions

Intervention 1: Intervention group: routin treatment +livergol tablets with a dose of 40 mg ,BID ,daily for patients with type 2 DM. Intervention 2: Control group:routin anti diabetes treatment with p

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 30_65 Diagnose of diabetics according of WHO criteria FBS >126 mg/dl or 2hpp>200 mg/dl or HbA1c>9% A history of DM is more than 1 year old FBS<250 Conscious informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Insulin therapy for autoimmune diseases and cancer Taking drugs that interfere with the level of plasma glucosesmoking Smoking Pregnancy and lactationcatching Hospitalized or undergoing surgery

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: Before and after of treatment. Method of measurement: Lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamdolah Sharifi

Oroumia University of Medical Sciences

Sharifi.h@umsu.ac.ir+98 44 3223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026